Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Normalization of dyrk1A and APP Function as an Approach to Improve Cognitive Performance and Decelerate AD Progression in DS Subjects: Epigallocatechin Gallate as Therapeutic Tool

NCT01699711 is registered in ClinicalTrials.gov with Parc de Salut Mar as lead sponsor.

NCT NCT01699711
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01699711 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Normalization of dyrk1A and APP Function as an Approach to Improve Cognitive Performance and Decelerate AD Progression in DS Subjects: Epigallocatechin Gallate as Therapeutic Tool
Lead sponsor
Parc de Salut Mar
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2012
Completion date
March 31, 2015
Enrollment
87 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

down syndrome (ds)